<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02640365</url>
  </required_header>
  <id_info>
    <org_study_id>DOUBLIRI C13-4</org_study_id>
    <nct_id>NCT02640365</nct_id>
  </id_info>
  <brief_title>A Dose Escalation Study of MM-398 Plus Irinotecan in Patients With Unresectable Advanced Cancer</brief_title>
  <acronym>DOUBLIRI</acronym>
  <official_title>A Phase Ib Dose Escalation Study of MM-398 Plus Irinotecan in Patients With Unresectable Advanced Cancer - DOUBLIRI</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GERCOR - Multidisciplinary Oncology Cooperative Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merrimack Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>GERCOR - Multidisciplinary Oncology Cooperative Group</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      MM-398 (also known as PEP02) is nanoliposomal encapsulated irinotecan: the liposomal&#xD;
      formulation is designed to extend plasma circulation and to increase accumulation in the&#xD;
      tumor through the enhanced permeability and retention (EPR) effect.&#xD;
&#xD;
      This study introduces a new concept of combining free and nanoliposomal drugs.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a dose-finding and therapeutic exploratory phase Ib multi-center, open label study of&#xD;
      MM-398 plus irinotecan in two different settings:&#xD;
&#xD;
        -  Group A : patients with unresectable advanced non-colorectal cancer who should receive&#xD;
           only MM-398 and irinotecan&#xD;
&#xD;
        -  Group B : patients with unresectable metastatic colorectal cancer who should receive&#xD;
           MM-398 and irinotecan combined with leucovorin, 5-fluorouracil and bevacizumab.&#xD;
&#xD;
      These groups will be enrolling in parallel. Pharmacokinetic and biomarker sampling will also&#xD;
      be performed.&#xD;
&#xD;
      There are three periods to this study :&#xD;
&#xD;
      Screening period (up to -28d): patients undergo screening assessments to determine the&#xD;
      eligibility for the study&#xD;
&#xD;
      MM-398 treatment period (C1D1 until safety evaluation/progression): patients receive&#xD;
      treatment every 2 weeks and undergo biopsies and other required assessments. The treatment&#xD;
      period is divided into a maximum of 3 dose levels&#xD;
&#xD;
      Follow up period: patients will be followed-up 30 days after their last dose of MM-398 for&#xD;
      final safety assessments, and every 2 months thereafter for overall survival follow-up&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 18, 2015</start_date>
  <completion_date type="Actual">December 7, 2016</completion_date>
  <primary_completion_date type="Actual">December 7, 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse Event (AE)</measure>
    <time_frame>Assessed from study inclusion to 30 days after last dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Dose Limiting Toxicities (DLT)</measure>
    <time_frame>DLTs will be evaluated during 28-day period following the first dose of study treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximal tolerated dose (MTD)</measure>
    <time_frame>after the last patient in each cohort up to 28 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response Rate (RR)</measure>
    <time_frame>tumor responses will be evaluated every 8 weeks after start treatment up to 29 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Best overall Response (BOR)</measure>
    <time_frame>BOR is the best response recorded from the inclusion until treatment failure up to 28 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>assessed from the date of inclusion to the date of patient death, due to any cause or to the last date the patient was known to be alive, up to 29 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival (PFS)</measure>
    <time_frame>PFS is the time from the date of inclusion to the date of progressive disease or death up to 29 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic of MM-398 plus irinotecan combination therapy</measure>
    <time_frame>cycle 1 Day 1 (1 cycle every 2 weeks) at Hour (H) 0, H+1, H+2.5, H+4.5, H+6.5, H+26.5, Day 3, Day 8, Day 15 and 30 days after the last dose of treatment</time_frame>
    <description>to determine the levels of MM-398/irinotecan, SN-38 and SN-38G</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Unresectable Advanced Cancer</condition>
  <arm_group>
    <arm_group_label>GROUP A / GROUP B (two differents cohorts)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GROUP A (Patients with unresectable advanced non-colorectal cancer ) - irinotecan + MM-398 dose escalation (3-18 patients)&#xD;
Level 1 : initial DOUBLIRI dose 60/90 (0-3 patients)&#xD;
MM-398 : 60mg/m²&#xD;
Irinotecan (CPT-11) : 90mg/m²&#xD;
Level 2: DOUBLIRI dose 80/90 (9 - 18 patients)&#xD;
MM-398 : 80mg/m²&#xD;
CPT-11: 90mg/m²&#xD;
Level 3A: DOUBLIRI dose 60/120 (12-18 patients)&#xD;
MM-398 : 60mg/m²&#xD;
CPT-11: 120mg/m²&#xD;
Level 3B: DOUBLIRI dose : 80/120 (12-18 patients)&#xD;
MM-398 : 80mg/m²&#xD;
CPT-11 : 120 mg/m²&#xD;
GROUP B (Patients with unresectable metastatic colorectal cancer)- LV/5FU-bevacizumab+irinotecan+MM-398 dose Escalation (3-18 patients)&#xD;
same level as group A + LV/5FU - bevacizumab regimen :&#xD;
Bevacizumab : 5mg/kg(day (d) 1)&#xD;
Leucovorin (LV) : 400mg/m² (d1)&#xD;
5-fluorouracile infusion (5 FU) :2400mg/m² (d1,2)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MM-398</intervention_name>
    <description>unresectable Advanced non-colorectal cancer</description>
    <arm_group_label>GROUP A / GROUP B (two differents cohorts)</arm_group_label>
    <other_name>GROUP A</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Irinotecan</intervention_name>
    <description>unresectable metastatic colorectal cancer</description>
    <arm_group_label>GROUP A / GROUP B (two differents cohorts)</arm_group_label>
    <other_name>GROUP A</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Leucovorin (LV)</intervention_name>
    <description>unresectable metastatic colorectal cancer</description>
    <arm_group_label>GROUP A / GROUP B (two differents cohorts)</arm_group_label>
    <other_name>GROUPE B</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5-fluorouracile (5-FU)</intervention_name>
    <description>unresectable metastatic colorectal cancer</description>
    <arm_group_label>GROUP A / GROUP B (two differents cohorts)</arm_group_label>
    <other_name>GROUPE B</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bevacizumab</intervention_name>
    <description>unresectable metastatic colorectal cancer</description>
    <arm_group_label>GROUP A / GROUP B (two differents cohorts)</arm_group_label>
    <other_name>GROUPE B</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MM-398</intervention_name>
    <description>unresectable metastatic colorectal cancer</description>
    <arm_group_label>GROUP A / GROUP B (two differents cohorts)</arm_group_label>
    <other_name>GROUPE B</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age 18 - 75 years&#xD;
&#xD;
          2. Histologically proven carcinoma,&#xD;
&#xD;
          3. Documented advanced or metastatic disease not suitable for complete surgical resection&#xD;
&#xD;
          4. Measurable or evaluable lesions according to RECIST v1.1 criteria&#xD;
&#xD;
          5. ECOG performance status 0 - 1&#xD;
&#xD;
          6. Adequate Bone marrow reserves as evidenced by:&#xD;
&#xD;
               -  Absolute Neutrophil Count (ANC) ≥1.5 x 109/L without the use of hematopoietic&#xD;
                  growth factors&#xD;
&#xD;
               -  platelets ≥ 100 x 109/L&#xD;
&#xD;
               -  hemoglobin &gt; 9 g/dL (may be transfused to maintain or exceed this level)&#xD;
&#xD;
          7. International Normalized Ratio (INR) ≤1.5; aPTT&lt;1.5 x upper normal limit (UNL);&#xD;
             EXEMPTION: patients on full anticoagulation therapy due to Venous Thromboembolism&#xD;
             (VTE) must have an in-range INR (usually between 2 and 3).&#xD;
&#xD;
          8. Adequate renal function as evidenced by:&#xD;
&#xD;
               -  serum creatinine: &lt; 150µmol/l&#xD;
&#xD;
               -  calculated creatinine clearance &gt; 50ml/min. (recommendation: to be calculated&#xD;
                  according to the MDRD formula)&#xD;
&#xD;
          9. Total bilirubin &lt; 1.0 x upper normal limit (UNL)&#xD;
&#xD;
         10. Normal ECG or ECG without any clinically significant findings&#xD;
&#xD;
         11. Regular follow-up feasible. A registered patient must be treated and followed at the&#xD;
             participating center.&#xD;
&#xD;
         12. Able to understand and sign an informed consent&#xD;
&#xD;
         13. No contraindication to any study drugs&#xD;
&#xD;
         14. Registration in a national health care system (CMU included for France). NB.: prior&#xD;
             exposure to irinotecan is allowed, except for irinotecan-refractory patients (i.e.&#xD;
             exclusion criteria)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Active central nervous system metastases (indicated by clinical symptoms, cerebral&#xD;
             edema, steroid requirement, or progressive disease)&#xD;
&#xD;
          2. Bone-only disease&#xD;
&#xD;
          3. Clinically significant gastrointestinal (GI) disorder including hepatic disorders,&#xD;
             bleeding, inflammation, GI obstruction, or diarrhea &gt; grade 1&#xD;
&#xD;
          4. Patients refractory to irinotecan (i.e. prior exposure to irinotecan-based therapy&#xD;
             with progressive disease as best response)&#xD;
&#xD;
          5. Known Dose Limiting Toxicity (DLT) responses to irinotecan&#xD;
&#xD;
          6. Patients known to be homozygous for UGT1A1 *28&#xD;
&#xD;
          7. History of any second malignancy in the last 3 years; patients with prior history of&#xD;
             in-situ cancer or basal or squamous cell skin cancer are eligible. Patients with a&#xD;
             history of other malignancies are eligible if they have been continuously disease-free&#xD;
             for at least 3 years&#xD;
&#xD;
          8. Prior exposure to MM-398&#xD;
&#xD;
          9. Known hypersensitivity to any of the components of MM-398, or other liposomal products&#xD;
&#xD;
         10. Concurrent illnesses that would be a relative contraindication to trial participation&#xD;
             such as active cardiac or liver disease&#xD;
&#xD;
               -  Severe arterial thromboembolic events (myocardial infarction, unstable angina&#xD;
                  pectoris, stroke) less than 6 months before inclusion&#xD;
&#xD;
               -  NYHA Class III or IV congestive heart failure, ventricular arrhythmias&#xD;
&#xD;
         11. Chronic inflammatory bowel disease and/or bowel obstruction&#xD;
&#xD;
         12. Active infection or an unexplained fever &gt;38.5°C during screening visits or on the&#xD;
             first scheduled day of dosing (at the discretion of the investigator, patients with&#xD;
             tumor fever may be enrolled), which in the investigator's opinion might compromise the&#xD;
             patient's participation in the trial or affect the study outcome&#xD;
&#xD;
         13. Prior chemotherapy administered within 3 weeks, or within a time interval less than at&#xD;
             least 5 half-lives of the agent, whichever is longer, prior to the first scheduled day&#xD;
             of dosing in this study&#xD;
&#xD;
         14. Uncontrolled hypertension (defined as persistent systolic blood pressure &gt;150 mmHg&#xD;
             and/or diastolic blood pressure &gt;100 mmHg), or history of hypertensive crisis, or&#xD;
             hypertensive encephalopathy&#xD;
&#xD;
         15. Received radiation therapy in the last 14 days&#xD;
&#xD;
         16. Major surgery or traumatic injury within the last 28 days&#xD;
&#xD;
         17. Any other medical or social condition deemed by the Investigator to be likely to&#xD;
             interfere with a patient's ability to sign informed consent, cooperate and participate&#xD;
             in the study, or interfere with the interpretation of the results including tutelage&#xD;
             and guardianship&#xD;
&#xD;
         18. Pregnant or breast feeding; females of child-bearing potential must test negative for&#xD;
             pregnancy at the time of enrollment based on a urine or serum pregnancy test. Both&#xD;
             male and female patients of reproductive potential must agree to use a reliable method&#xD;
             of birth control, during the study and for 6 months following the last dose of study&#xD;
             drug.&#xD;
&#xD;
         19. Concomitant administrations use with St John Worth, or CYP3A4 inducing anticonvulsants&#xD;
             (phenytoin, Phenobarbital, carbamazepine), ketoconazole, itraconazole, troleandomycin,&#xD;
             erythromycin, diltiazem and verapamil&#xD;
&#xD;
         20. Concomitant administration of live attenuated virus vaccine such as yellow fever&#xD;
             vaccine&#xD;
&#xD;
         21. Known dihydropyrimidine dehydrogenase (DPD) deficiency&#xD;
&#xD;
         22. Known active hepatitis B or C and/or active or chronic human immunodeficiency virus&#xD;
             (HIV)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Benoist Chibaudel, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Franco-British Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hôpital Saint Antoine</name>
      <address>
        <city>Paris</city>
        <zip>75012</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <study_first_submitted>December 16, 2015</study_first_submitted>
  <study_first_submitted_qc>December 21, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 28, 2015</study_first_posted>
  <last_update_submitted>January 30, 2017</last_update_submitted>
  <last_update_submitted_qc>January 30, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 31, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>cancer</keyword>
  <keyword>GERCOR</keyword>
  <keyword>unresectable</keyword>
  <keyword>MM-398</keyword>
  <keyword>CPT-11</keyword>
  <keyword>colorectal</keyword>
  <keyword>non colorectal</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leucovorin</mesh_term>
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Irinotecan</mesh_term>
    <mesh_term>Camptothecin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <pending_results>
    <submitted>May 25, 2021</submitted>
    <returned>June 17, 2021</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

